1. Home
  2. NBIX vs RDY Comparison

NBIX vs RDY Comparison

Compare NBIX & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$130.61

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Logo Dr. Reddy's Laboratories Ltd

RDY

Dr. Reddy's Laboratories Ltd

HOLD

Current Price

$13.14

Market Cap

11.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBIX
RDY
Founded
1992
1984
Country
United States
India
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2B
11.6B
IPO Year
1996
2001

Fundamental Metrics

Financial Performance
Metric
NBIX
RDY
Price
$130.61
$13.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
22
1
Target Price
$180.82
$16.90
AVG Volume (30 Days)
901.1K
2.1M
Earning Date
05-04-2026
05-08-2026
Dividend Yield
N/A
0.54%
EPS Growth
41.95
N/A
EPS
4.67
N/A
Revenue
$161,626,000.00
N/A
Revenue This Year
$22.85
$7.81
Revenue Next Year
$10.36
$3.20
P/E Ratio
$27.09
$18.67
Revenue Growth
977.51
N/A
52 Week Low
$97.30
$12.82
52 Week High
$160.18
$16.17

Technical Indicators

Market Signals
Indicator
NBIX
RDY
Relative Strength Index (RSI) 50.14 39.30
Support Level $124.29 $12.93
Resistance Level $136.23 $14.14
Average True Range (ATR) 4.29 0.23
MACD -0.08 -0.02
Stochastic Oscillator 59.64 26.75

Price Performance

Historical Comparison
NBIX
RDY

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

About RDY Dr. Reddy's Laboratories Ltd

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Share on Social Networks: